Floatz logo

Eloxatin

B-cell Malignancy

BeOne MedicinesPhase 1/2Active
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
89/ 100

Competitive context

8 Active assets in the B-cell Malignancy cohort.

Asset / SponsorPhaseRating
ctx110
CRISPR Therapeutics AG
Phase 1/2CC
Bgb-16673
BeOne Medicines
Phase 1/2CC
Sonrotoclax
BeOne Medicines
Phase 1/2CC
Mosunetuzumab
BeOne Medicines
Phase 1/2CC
ctx112
CRISPR Therapeutics AG
Phase 1/2CC

View all 10 →

Same molecule, other indications

Eloxatin is also rated in:

exocrine pancreatic carcinomaDormant
BBB
Indicative ·
78 / 100
View asset →
colon adenocarcinomaDormant
BBB
Indicative ·
77 / 100
View asset →
colorectal neoplasmDormant
BBB
Indicative ·
74 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →